Clementia is a biopharmaceutical company dedicated to bringing effective new treatments to people who have none.
We are rapidly developing our first lead product candidate, palovarotene, to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling disorder, and other diseases.
We believe that palovarotene holds significant potential for individuals with FOP and are currently investigating the oral compound in Phase 2 clinical trials. We strive to work with bold efficiency and hand-in-hand with physicians and disease communities to chart a new course in drug development.
Our name, Clementia, is derived from the Latin word for compassion or empathy – a concept that inspires everything we do.
Founded in 2011, Clementia is a privately held biopharmaceutical company headquartered in Montreal, Canada with a U.S. subsidiary in Boston, MA.